PHARMACY

Diplomat to dispense Kisqali

BY David Salazar
FLINT, Mich. — Diplomat on Thursday announced availability of a new top-line treatment for metastatic breast cancer. The specialty pharmacy will dispense Kisqali, which was recently approved by the Food and Drug Administration. 
 
Kisqali is a once-daily oral therapy for postmenopausal women with advanced of metastatic breast cancer that’s hormone-receptor positive and negative for human epidermal growth factor receptor 2. It’s meant to be used in combination with an aromatase inhibitor. 
 
“The diagnosis of advanced or metastatic breast cancer has a devastating impact on patients, as well as their loved ones,” Diplomat president Paul Urick said. “Kisqali is a groundbreaking new treatment that can improve quality of life for our patients.”
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

OmniSYS acquires voiceTech, Fusion-Rx platform

BY David Salazar

DALLAS — Medical claims billing, Medicare compliance and pharmacy patient engagement solutions company OmniSYS recently added to its suite of pharmacy solutions. The company acquired voiceTech, bringing the Fusion-Rx platform into the company’s fold.

“In keeping with our mission to improve the health of healthcare, we are always looking for ways to expand our portfolio in order to deliver added value to our pharmacy customers and the patients they serve,” OmniSYS CEO John King said. “That is why we are excited to announce our recent acquisition of voiceTech and its Fusion-Rx platform.”

Fusion-Rx is a patient adherence and communication tool that integrates inbound IVR and Star rating outbound messaging, bringing 24/7 pharmacy access over the phone, online and on mobile devices, the company said.

“This new technology complements our existing solutions — CareCLAIM, OmniLINK, and Analytix — and enhances our patient engagement capabilities,” King said.  “It also features cloud-based API connectivity to over 60 pharmacy management systems, enabling us to access an expanded dataset, including prescription data that will lead to new engagement opportunities and enhanced business insight.”

As a result of the acquisition, OmniSYS will expand its office locations to include a second operations center in Sarasota, Fla. The company currently has an existing operations center in Greenville, Texas, and corporate headquarters in Dallas. To ensure a seamless transition and the integration of Fusion-Rx into the OmniSYS portfolio, the company said key voiceTech executives would remain with the company.

“We are proud to become part of the OmniSYS family,” voiceTech co-founder and president Tim Garofalo said. “Our companies have similar values and a shared commitment to the industry. With a focus on expanding patient engagement, our blended solution offers promising opportunities for both pharmacies and our company.”
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Adapt Pharma highlights naloxone nasal spray efficacy at AAPM

BY David Salazar
ORLANDO, Fla. — A little more than a year after its approval, Adapt Pharma made the case for the effectiveness of its Narcan (naoloxone) Nasal Spray 4 mg at the annual American Academy of Pain Medicine, here, on Thursday with real-world use data. The survey collected case data and outcomes of opioid overdose reversal attempts by first responders and community health organizations using the nasal spray. 
 
Of the 261 attempted reversals reported and analyzed, 245 recorded a known clinical outcome, with 242 reported as successful following administration of the nasal spray. More than 95% of the cases were presumed to involve a heroin overdose, and 5% involved fentanyl. In 74.5% of the cases analyzed, response time after naloxone administration was less than five minutes, which Adapt says is consistent with responses seen in patients receiving an intramuscular naloxone administration.
 
“We are pleased to have real-world experiences and outcomes with Narcan Nasal Spray presented at AAPM”, Adapt Pharma CEO Seamus Mulligan said. “Narcan Nasal Spray was designed to be administered in an emergency by people without specialized medical training.”
 
Albertsons recently announced that it had trained pharmacists across its banners in 13 states to dispense Adapt Pharma’s nasal spray without a prescription. The nasal spray was approved by the Food and Drug Administration under priority review and launched in February 2016. 
 
“With our teams in place as a resource for this medication, we are keeping with our commitment to serve and improve the health and wellness of all our customers while also making our communities stronger," Mark Panzer, Albertsons SVP pharmacy, health and wellness, said when Albertsons announced its naloxone nasal spray availability. 
 
With the Centers for Disease Control and Prevention estimating that 78 Americans die daily from drug overdoses, naloxone availability has been a big effort among drug store chains, with CVS pharmacists dispensing naloxone injections for patients without prescriptions in 41 states, Rite Aid making it available in 23 states and Walgreens patients able to get naloxone prescription-free in more than 34 states and Washington, D.C. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES